The inhibition of postinfarct ventricle remodeling without polycythaemia following local sustained intramyocardial delivery of erythropoietin within a supramolecular hydrogel

Biomaterials

Volumn 30, Issue 25, 2009, Pages 4161-4167

  Wang, Tao ^a   Jiang, Xue Jun ^a   Lin, Tao ^a   Ren, Shan ^a   Li, Xiao Yan ^a   Zhang, Xian Zheng ^b   Tang, Qi zhu ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

Erythropoietin; Hydrogel; Local sustained delivery; Myocardial infarction; Polycythaemia

Indexed keywords

ADVERSE EFFECT; BIOACTIVE AGENTS; CARDIAC FUNCTIONS; CARDIOPROTECTIVE EFFECT; CELL APOPTOSIS; ERYTHROPOIETIN; HUMAN ERYTHROPOIETIN; INFARCT SIZE; ISCHEMIC INJURIES; LOCAL SUSTAINED DELIVERY; MYOCARDIAL INFARCTION; NEOVASCULATURE; PERFORMANCE IMPROVEMENTS; PHOSPHATE-BUFFERED SOLUTIONS; POLYCYTHAEMIA; SUPRAMOLECULAR HYDROGELS; SUSTAINED RELEASE;

ANIMALS; BIOLOGICAL MATERIALS; CELL DEATH; MOTION PICTURE EXPERTS GROUP STANDARDS;

HYDROGELS;

ALPHA CYCLODEXTRIN; MACROGOL DERIVATIVE; PHOSPHATE BUFFERED SALINE; POLYCAPROLACTONE; POLYMER; RECOMBINANT ERYTHROPOIETIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ERYTHROCYTE COUNT; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART PERFORMANCE; HEART PROTECTION; HEART VENTRICLE REMODELING; HEMATOCRIT; HYDROGEL; MALE; NONHUMAN; POLYCYTHEMIA; PRIORITY JOURNAL; RAT; SUPRAMOLECULAR CHEMISTRY; SUSTAINED DRUG RELEASE;

ALPHA-CYCLODEXTRINS; ANIMALS; APOPTOSIS; BIOCOMPATIBLE MATERIALS; CARDIOTONIC AGENTS; DRUG CARRIERS; ECHOCARDIOGRAPHY; ERYTHROPOIETIN; HEMODYNAMICS; HUMANS; HYDROGELS; MALE; MATERIALS TESTING; MYOCARDIAL INFARCTION; MYOCARDIUM; NEOVASCULARIZATION, PHYSIOLOGIC; POLYCYTHEMIA; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; STEM CELLS; VENTRICULAR REMODELING;

ANIMALIA; RATTUS;

EID: 67649834505     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2009.04.033     Document Type: Article

References (35)

1. Sun Y., and Weber K.T. Infarct scar: a dynamic tissue. Cardiovasc Res 46 (2000) 250-256
2. Mann D.L. Mechanisms and models in heart failure: a combinatorial approach. Circulation 100 (1999) 999-1008
3. Henry D.H., Bowers P., Romano M.T., and Provenzano R. Epoetin alfa. Clinical evolution of a pleiotropic cytokine. Arch Intern Med 164 (2004) 262-276
4. Jelkmann W., and Wagner K. Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 83 (2004) 673-686
5. Smith K.J., Bleyer A.J., Little W.C., and Sane D.C. The cardiovascular effects of erythropoietin. Cardiovasc Res 59 (2003) 538-548
6. Hirata A., Minamino T., Asanuma H., Fujita M., Wakeno M., Myoishi M., et al. Erythropoietin enhances neovascularization of ischemic myocardium and improves left ventricular dysfunction after myocardial infarction in dogs. J Am Coll Cardiol 48 (2006) 176-184
7. Lipsic E., Schoemaker R.G., van der Meer P., Voors A.A., van Veldhuisen D.J., and van Gilst W.H. Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J Am Coll Cardiol 48 (2006) 2161-2167
8. Van der Meer P., Voors A.A., Lipsic E., van Gilst W.H., and van Veldhuisen D.J. Erythropoietin in cardiovascular diseases. Eur Heart J 25 (2004) 285-291
9. Besarab A., Bolton W.K., Browne J.K., Egrie J.C., Nissenson A.R., Okamoto D.M., et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and bepoetin. N Engl J Med 339 (1998) 584-590
10. Rao S.V., and Stamler J.S. Erythropoietin, anemia, and orthostatic hypotension: the evidence mounts. Clin Auton Res 12 (2002) 141-143
11. Viron B., Chamma F., Jaar B., Michel C., and Mignon F. Thrombosis of angioaccess in haemodialysed patients treated with human recombinant erythropoietin. Nephrol Dial Transplant 12 (1997) 368-370
12. Christman K.L., and Lee R.J. Biomaterials for the treatment of myocardial infarction. J Am Coll Cardiol 48 (2006) 907-913
13. Putnam D. The heart of the matter: a polymeric delivery vehicle, with neutral degradation products, keeps inflammation at bay during sustained drug release following myocardial infarction. Nat Mater 7 (2008) 836-837
14. Hsieh P.C., Davis M.E., Gannon J., MacGillivray C., and Lee R.T. Controlled delivery of PDGF-BB for myocardial protection using injectable selfassembling peptide nanofibers. J Clin Invest 116 (2006) 237-248
15. Iwakura A., Fujita M., Kataoka K., Tambara K., Sakakibara Y., Komeda M., et al. Intramyocardial sustained delivery of basic fibroblast growth factor improves angiogenesis and ventricular function in a rat infarct model. Heart Vessels 18 (2003) 93-99
16. Wu D.Q., Wang T., Lu B., Xu X.D., Cheng S.X., Jiang X.J., et al. Fabrication of supramolecular hydrogels for drug delivery and stem cell encapsulation. Langmuir 24 (2008) 10306-10312
17. Jiang X., Wang T., Li X., Wu D., Zheng Z.B., Zhang J.F., et al. Injection of a novel synthetic hydrogel preserves left ventricle function after myocardial infarction. J Biomed Mater Res A (2008 Jun 10) 10.1002/jbm.a.32118 [epub ahead of print]
18. Hao X., Silva E.A., Mansson-Broberg A., Grinnemo K.H., Siddiqui A.J., Dellgren G., et al. Angiogenic effects of sequential release of VEGF-A(165) and PDGF-BB with alginate hydrogels after myocardial infarction. Cardiovasc Res 75 (2007) 178-185
19. Bogoyevitch M.A. An update on the cardiac effects of erythropoietin cardioprotection by erythropoietin and the lessons learnt from studies in neuroprotection. Cardiovasc Res 63 (2004) 208-216
20. Parsa C.J., Matsumoto A., Kim J., Riel R.U., Pascal L.S., Walton G.B., et al. A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112 (2003) 999-1007
21. Heeschen C., Aicher A., Lehmann R., Fichtlscherer S., Vasa M., Urbich C., et al. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 102 (2003) 1340-1346
22. Westenbrink B.D., Lipsic E., van der Meer P., van der Harst P., Oeseburg H., Du Marchie Sarvaas G.J., et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur Heart J 28 (2007) 2018-2027
23. Prunier F., Pfister O., Hadri L., Liang L., Del Monte F., Liao R., et al. Delayed erythropoietin therapy reduces post-MI cardiac remodeling only at a dose that mobilizes endothelial progenitor cells. Am J Physiol Heart Circ Physiol 292 (2007) 522-529
24. Hsieh P.C., MacGillivray C., Gannon J., Cruz F.U., and Lee R.T. Local controlled intramyocardial delivery of platelet-derived growth factor improves postinfarction ventricular function without pulmonary toxicity. Circulation 114 (2006) 637-644
25. Christman K.L., Fok H.H., Sievers R.E., Fang Q., and Lee R.J. Fibrin glue alone and skeletal myoblasts in a fibrin scaffold preserve cardiac function after myocardial infarction. Tissue Eng 10 (2004) 403-409
26. Landa N., Miller L., Feinberg M.S., Holbova R., Shachar M., Freeman I., et al. Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 117 (2008) 1388-1396
27. Huang N.F., Yu J., Sievers R., Li S., and Lee R.J. Injectable biopolymers enhance angiogenesis after myocardial infarction. Tissue Eng 11 (2005) 1860-1866
28. Dai W., Wold L.E., Dow J.S., and Kloner R.A. Thickening of the infracted wall by collagen injection improves left ventricular function in rats: a novel approach to preserve cardiac function after myocardial infarction. J Am Coll Cardiol 46 (2005) 714-719
29. Davis M.E., Motion J.P., Narmoneva D.A., Takahashi T., Hakuno D., Kamm R.D., et al. Injectable self-assembling peptide nanofibers create intramyocardial microenvironments for endothelial cells. Circulation 111 (2005) 442-450
30. Davis M.E., Hsieh P.C., Takahashi T., Song Q., Zhang S.G., Kamm R.D., et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A 103 (2006) 8155-8160
31. Segers V.F., Tokunou T., Higgins L.J., MacGillivray C., Gannon J., and Lee R.T. Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. Circulation 116 (2007) 1683-1692
32. Lipsic E., van der Meer P., and Voors A.A. A single bolus of a long-acting erythropoietin analogue darbepoetin alfa in patients with acute myocardial infarction: a randomized feasibility and safety study. Cardiovasc Drugs Ther 20 (2006) 135-141
33. Kobayashi H., Minatoguchi S., Yasuda S., Bao N., Kawamura I., Iwasa M., et al. Post-infarct treatment with an erythropoietin-gelatin hydrogel drug delivery system for cardiac repair. Cardiovasc Res 79 (2008) 611-620
34. Schneider C., Jaquet K., Malisius R., Geidel S., Bahlmann E., Boczor S., et al. Attenuation of cardiac remodelling by endocardial injection of erythropoietin: ultrasonic strain-rate imaging in a model of hibernating myocardium. Eur Heart J 28 (2007) 499-509
35. Krause K.T., Jaquet K., Geidel S., Schneider C., Mandel C., Stoll H.P., et al. Percutaneous endocardial injection of erythropoietin: assessment of cardioprotection by electromechanical mapping. Eur J Heart Fail 8 (2006) 443-450